Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/JCO.1988.6.7.1204 | DOI Listing |
EuroIntervention
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Background: Microvascular angina (MVA) is an important contributor to morbidity and mortality in patients with non-obstructive coronary artery disease. Despite improvements in its recognition and diagnosis, uncertainty remains around the most effective treatment strategy, and more data are needed.
Aims: We aimed to evaluate the quality of patient selection in treatment studies of MVA and provide a contemporary overview of the evidence base for the treatment of MVA.
Heart
December 2024
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna, Italy
Catheter Cardiovasc Interv
December 2024
Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA.
Background: Coronary microvascular and vasomotor dysfunction (CMVD) is associated with a threefold increased risk of major adverse cardiovascular events (MACE) and is the primary mechanism responsible for angina/ischemia in patients with nonobstructive coronary artery disease (ANOCA/INOCA). Proper assessment for CMVD is vital to provide targeted treatment and improve patient outcomes. Invasive coronary functional testing (ICFT) is the "gold standard," for CMVD assessment and can be used to diagnose all endotypes.
View Article and Find Full Text PDFPLoS One
October 2024
Performance and Health Group, Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, A Coruña, Spain.
J Neurophysiol
November 2024
Macquarie Medical School, Faculty of Medicine, Health and Human SciencesMacquarie University, Sydney, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!